Filing Details

Accession Number:
0001764013-22-000130
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-17 08:57:50
Reporting Period:
2022-10-13
Accepted Time:
2022-10-17 08:57:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1764013 Immunovant Inc. IMVT Biological Products, (No Disgnostic Substances) (2836) 832771572
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1796309 Peter Salzmann C/O Immunovant, Inc.
320 W 37Th Street, 6Th Floor
New York NY 10018
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-10-13 2,793 $9.18 997,953 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2022 and the remainder of the RSUs vest in quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
  2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.18 - $9.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.